Global Anti-VEGF Therapies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 88

Published Date: 25 Jul 2024

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

According to our (Global Info Research) latest study, the global Anti-VEGF Therapies market size was valued at US$ 866 million in 2023 and is forecast to a readjusted size of USD 1341 million by 2030 with a CAGR of 6.2% during review period.

This report is a detailed and comprehensive analysis for global Anti-VEGF Therapies market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Anti-VEGF Therapies market size and forecasts, in consumption value ($ Million), 2019-2030
Global Anti-VEGF Therapies market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Anti-VEGF Therapies market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Anti-VEGF Therapies market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-VEGF Therapies
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-VEGF Therapies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Novartis, Alphamab Oncology, Chengdu Kanghong Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation
Anti-VEGF Therapies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation
Anti-VEGF Therapies market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Bevacizumab
    Ramucirumab
    Ranibizumab
    Aflibercept
    Conbercept
    Other

Market segment by Application
    Hospitals
    Clinics

Market segment by players, this report covers
    Roche
    Eli Lilly
    Pfizer
    Regeneron Pharmaceuticals
    Novartis
    Alphamab Oncology
    Chengdu Kanghong Pharmaceutical

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Anti-VEGF Therapies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Anti-VEGF Therapies, with revenue, gross margin, and global market share of Anti-VEGF Therapies from 2019 to 2024.
Chapter 3, the Anti-VEGF Therapies competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Anti-VEGF Therapies market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Anti-VEGF Therapies.
Chapter 13, to describe Anti-VEGF Therapies research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Anti-VEGF Therapies by Type
        1.3.1 Overview: Global Anti-VEGF Therapies Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Anti-VEGF Therapies Consumption Value Market Share by Type in 2023
        1.3.3 Bevacizumab
        1.3.4 Ramucirumab
        1.3.5 Ranibizumab
        1.3.6 Aflibercept
        1.3.7 Conbercept
        1.3.8 Other
    1.4 Global Anti-VEGF Therapies Market by Application
        1.4.1 Overview: Global Anti-VEGF Therapies Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospitals
        1.4.3 Clinics
    1.5 Global Anti-VEGF Therapies Market Size & Forecast
    1.6 Global Anti-VEGF Therapies Market Size and Forecast by Region
        1.6.1 Global Anti-VEGF Therapies Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Anti-VEGF Therapies Market Size by Region, (2019-2030)
        1.6.3 North America Anti-VEGF Therapies Market Size and Prospect (2019-2030)
        1.6.4 Europe Anti-VEGF Therapies Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Anti-VEGF Therapies Market Size and Prospect (2019-2030)
        1.6.6 South America Anti-VEGF Therapies Market Size and Prospect (2019-2030)
        1.6.7 Middle East & Africa Anti-VEGF Therapies Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 Roche
        2.1.1 Roche Details
        2.1.2 Roche Major Business
        2.1.3 Roche Anti-VEGF Therapies Product and Solutions
        2.1.4 Roche Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Roche Recent Developments and Future Plans
    2.2 Eli Lilly
        2.2.1 Eli Lilly Details
        2.2.2 Eli Lilly Major Business
        2.2.3 Eli Lilly Anti-VEGF Therapies Product and Solutions
        2.2.4 Eli Lilly Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Eli Lilly Recent Developments and Future Plans
    2.3 Pfizer
        2.3.1 Pfizer Details
        2.3.2 Pfizer Major Business
        2.3.3 Pfizer Anti-VEGF Therapies Product and Solutions
        2.3.4 Pfizer Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Pfizer Recent Developments and Future Plans
    2.4 Regeneron Pharmaceuticals
        2.4.1 Regeneron Pharmaceuticals Details
        2.4.2 Regeneron Pharmaceuticals Major Business
        2.4.3 Regeneron Pharmaceuticals Anti-VEGF Therapies Product and Solutions
        2.4.4 Regeneron Pharmaceuticals Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
    2.5 Novartis
        2.5.1 Novartis Details
        2.5.2 Novartis Major Business
        2.5.3 Novartis Anti-VEGF Therapies Product and Solutions
        2.5.4 Novartis Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Novartis Recent Developments and Future Plans
    2.6 Alphamab Oncology
        2.6.1 Alphamab Oncology Details
        2.6.2 Alphamab Oncology Major Business
        2.6.3 Alphamab Oncology Anti-VEGF Therapies Product and Solutions
        2.6.4 Alphamab Oncology Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Alphamab Oncology Recent Developments and Future Plans
    2.7 Chengdu Kanghong Pharmaceutical
        2.7.1 Chengdu Kanghong Pharmaceutical Details
        2.7.2 Chengdu Kanghong Pharmaceutical Major Business
        2.7.3 Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Product and Solutions
        2.7.4 Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Chengdu Kanghong Pharmaceutical Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Anti-VEGF Therapies Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Anti-VEGF Therapies by Company Revenue
        3.2.2 Top 3 Anti-VEGF Therapies Players Market Share in 2023
        3.2.3 Top 6 Anti-VEGF Therapies Players Market Share in 2023
    3.3 Anti-VEGF Therapies Market: Overall Company Footprint Analysis
        3.3.1 Anti-VEGF Therapies Market: Region Footprint
        3.3.2 Anti-VEGF Therapies Market: Company Product Type Footprint
        3.3.3 Anti-VEGF Therapies Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Anti-VEGF Therapies Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Anti-VEGF Therapies Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Anti-VEGF Therapies Consumption Value Market Share by Application (2019-2024)
    5.2 Global Anti-VEGF Therapies Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Anti-VEGF Therapies Consumption Value by Type (2019-2030)
    6.2 North America Anti-VEGF Therapies Market Size by Application (2019-2030)
    6.3 North America Anti-VEGF Therapies Market Size by Country
        6.3.1 North America Anti-VEGF Therapies Consumption Value by Country (2019-2030)
        6.3.2 United States Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        6.3.3 Canada Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        6.3.4 Mexico Anti-VEGF Therapies Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Anti-VEGF Therapies Consumption Value by Type (2019-2030)
    7.2 Europe Anti-VEGF Therapies Consumption Value by Application (2019-2030)
    7.3 Europe Anti-VEGF Therapies Market Size by Country
        7.3.1 Europe Anti-VEGF Therapies Consumption Value by Country (2019-2030)
        7.3.2 Germany Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        7.3.3 France Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        7.3.5 Russia Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        7.3.6 Italy Anti-VEGF Therapies Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Anti-VEGF Therapies Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Anti-VEGF Therapies Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Anti-VEGF Therapies Market Size by Region
        8.3.1 Asia-Pacific Anti-VEGF Therapies Consumption Value by Region (2019-2030)
        8.3.2 China Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        8.3.3 Japan Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        8.3.4 South Korea Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        8.3.5 India Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        8.3.7 Australia Anti-VEGF Therapies Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Anti-VEGF Therapies Consumption Value by Type (2019-2030)
    9.2 South America Anti-VEGF Therapies Consumption Value by Application (2019-2030)
    9.3 South America Anti-VEGF Therapies Market Size by Country
        9.3.1 South America Anti-VEGF Therapies Consumption Value by Country (2019-2030)
        9.3.2 Brazil Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        9.3.3 Argentina Anti-VEGF Therapies Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Anti-VEGF Therapies Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Anti-VEGF Therapies Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Anti-VEGF Therapies Market Size by Country
        10.3.1 Middle East & Africa Anti-VEGF Therapies Consumption Value by Country (2019-2030)
        10.3.2 Turkey Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Anti-VEGF Therapies Market Size and Forecast (2019-2030)
        10.3.4 UAE Anti-VEGF Therapies Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Anti-VEGF Therapies Market Drivers
    11.2 Anti-VEGF Therapies Market Restraints
    11.3 Anti-VEGF Therapies Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Anti-VEGF Therapies Industry Chain
    12.2 Anti-VEGF Therapies Upstream Analysis
    12.3 Anti-VEGF Therapies Midstream Analysis
    12.4 Anti-VEGF Therapies Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Anti-VEGF Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Anti-VEGF Therapies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Global Anti-VEGF Therapies Consumption Value by Region (2019-2024) & (USD Million)
 Table 4. Global Anti-VEGF Therapies Consumption Value by Region (2025-2030) & (USD Million)
 Table 5. Roche Company Information, Head Office, and Major Competitors
 Table 6. Roche Major Business
 Table 7. Roche Anti-VEGF Therapies Product and Solutions
 Table 8. Roche Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 9. Roche Recent Developments and Future Plans
 Table 10. Eli Lilly Company Information, Head Office, and Major Competitors
 Table 11. Eli Lilly Major Business
 Table 12. Eli Lilly Anti-VEGF Therapies Product and Solutions
 Table 13. Eli Lilly Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 14. Eli Lilly Recent Developments and Future Plans
 Table 15. Pfizer Company Information, Head Office, and Major Competitors
 Table 16. Pfizer Major Business
 Table 17. Pfizer Anti-VEGF Therapies Product and Solutions
 Table 18. Pfizer Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 19. Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors
 Table 20. Regeneron Pharmaceuticals Major Business
 Table 21. Regeneron Pharmaceuticals Anti-VEGF Therapies Product and Solutions
 Table 22. Regeneron Pharmaceuticals Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 23. Regeneron Pharmaceuticals Recent Developments and Future Plans
 Table 24. Novartis Company Information, Head Office, and Major Competitors
 Table 25. Novartis Major Business
 Table 26. Novartis Anti-VEGF Therapies Product and Solutions
 Table 27. Novartis Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 28. Novartis Recent Developments and Future Plans
 Table 29. Alphamab Oncology Company Information, Head Office, and Major Competitors
 Table 30. Alphamab Oncology Major Business
 Table 31. Alphamab Oncology Anti-VEGF Therapies Product and Solutions
 Table 32. Alphamab Oncology Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 33. Alphamab Oncology Recent Developments and Future Plans
 Table 34. Chengdu Kanghong Pharmaceutical Company Information, Head Office, and Major Competitors
 Table 35. Chengdu Kanghong Pharmaceutical Major Business
 Table 36. Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Product and Solutions
 Table 37. Chengdu Kanghong Pharmaceutical Anti-VEGF Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 38. Chengdu Kanghong Pharmaceutical Recent Developments and Future Plans
 Table 39. Global Anti-VEGF Therapies Revenue (USD Million) by Players (2019-2024)
 Table 40. Global Anti-VEGF Therapies Revenue Share by Players (2019-2024)
 Table 41. Breakdown of Anti-VEGF Therapies by Company Type (Tier 1, Tier 2, and Tier 3)
 Table 42. Market Position of Players in Anti-VEGF Therapies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 43. Head Office of Key Anti-VEGF Therapies Players
 Table 44. Anti-VEGF Therapies Market: Company Product Type Footprint
 Table 45. Anti-VEGF Therapies Market: Company Product Application Footprint
 Table 46. Anti-VEGF Therapies New Market Entrants and Barriers to Market Entry
 Table 47. Anti-VEGF Therapies Mergers, Acquisition, Agreements, and Collaborations
 Table 48. Global Anti-VEGF Therapies Consumption Value (USD Million) by Type (2019-2024)
 Table 49. Global Anti-VEGF Therapies Consumption Value Share by Type (2019-2024)
 Table 50. Global Anti-VEGF Therapies Consumption Value Forecast by Type (2025-2030)
 Table 51. Global Anti-VEGF Therapies Consumption Value by Application (2019-2024)
 Table 52. Global Anti-VEGF Therapies Consumption Value Forecast by Application (2025-2030)
 Table 53. North America Anti-VEGF Therapies Consumption Value by Type (2019-2024) & (USD Million)
 Table 54. North America Anti-VEGF Therapies Consumption Value by Type (2025-2030) & (USD Million)
 Table 55. North America Anti-VEGF Therapies Consumption Value by Application (2019-2024) & (USD Million)
 Table 56. North America Anti-VEGF Therapies Consumption Value by Application (2025-2030) & (USD Million)
 Table 57. North America Anti-VEGF Therapies Consumption Value by Country (2019-2024) & (USD Million)
 Table 58. North America Anti-VEGF Therapies Consumption Value by Country (2025-2030) & (USD Million)
 Table 59. Europe Anti-VEGF Therapies Consumption Value by Type (2019-2024) & (USD Million)
 Table 60. Europe Anti-VEGF Therapies Consumption Value by Type (2025-2030) & (USD Million)
 Table 61. Europe Anti-VEGF Therapies Consumption Value by Application (2019-2024) & (USD Million)
 Table 62. Europe Anti-VEGF Therapies Consumption Value by Application (2025-2030) & (USD Million)
 Table 63. Europe Anti-VEGF Therapies Consumption Value by Country (2019-2024) & (USD Million)
 Table 64. Europe Anti-VEGF Therapies Consumption Value by Country (2025-2030) & (USD Million)
 Table 65. Asia-Pacific Anti-VEGF Therapies Consumption Value by Type (2019-2024) & (USD Million)
 Table 66. Asia-Pacific Anti-VEGF Therapies Consumption Value by Type (2025-2030) & (USD Million)
 Table 67. Asia-Pacific Anti-VEGF Therapies Consumption Value by Application (2019-2024) & (USD Million)
 Table 68. Asia-Pacific Anti-VEGF Therapies Consumption Value by Application (2025-2030) & (USD Million)
 Table 69. Asia-Pacific Anti-VEGF Therapies Consumption Value by Region (2019-2024) & (USD Million)
 Table 70. Asia-Pacific Anti-VEGF Therapies Consumption Value by Region (2025-2030) & (USD Million)
 Table 71. South America Anti-VEGF Therapies Consumption Value by Type (2019-2024) & (USD Million)
 Table 72. South America Anti-VEGF Therapies Consumption Value by Type (2025-2030) & (USD Million)
 Table 73. South America Anti-VEGF Therapies Consumption Value by Application (2019-2024) & (USD Million)
 Table 74. South America Anti-VEGF Therapies Consumption Value by Application (2025-2030) & (USD Million)
 Table 75. South America Anti-VEGF Therapies Consumption Value by Country (2019-2024) & (USD Million)
 Table 76. South America Anti-VEGF Therapies Consumption Value by Country (2025-2030) & (USD Million)
 Table 77. Middle East & Africa Anti-VEGF Therapies Consumption Value by Type (2019-2024) & (USD Million)
 Table 78. Middle East & Africa Anti-VEGF Therapies Consumption Value by Type (2025-2030) & (USD Million)
 Table 79. Middle East & Africa Anti-VEGF Therapies Consumption Value by Application (2019-2024) & (USD Million)
 Table 80. Middle East & Africa Anti-VEGF Therapies Consumption Value by Application (2025-2030) & (USD Million)
 Table 81. Middle East & Africa Anti-VEGF Therapies Consumption Value by Country (2019-2024) & (USD Million)
 Table 82. Middle East & Africa Anti-VEGF Therapies Consumption Value by Country (2025-2030) & (USD Million)
 Table 83. Global Key Players of Anti-VEGF Therapies Upstream (Raw Materials)
 Table 84. Global Anti-VEGF Therapies Typical Customers


List of Figures
 Figure 1. Anti-VEGF Therapies Picture
 Figure 2. Global Anti-VEGF Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Anti-VEGF Therapies Consumption Value Market Share by Type in 2023
 Figure 4. Bevacizumab
 Figure 5. Ramucirumab
 Figure 6. Ranibizumab
 Figure 7. Aflibercept
 Figure 8. Conbercept
 Figure 9. Other
 Figure 10. Global Anti-VEGF Therapies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 11. Anti-VEGF Therapies Consumption Value Market Share by Application in 2023
 Figure 12. Hospitals Picture
 Figure 13. Clinics Picture
 Figure 14. Global Anti-VEGF Therapies Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 15. Global Anti-VEGF Therapies Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 16. Global Market Anti-VEGF Therapies Consumption Value (USD Million) Comparison by Region (2019 VS 2023 VS 2030)
 Figure 17. Global Anti-VEGF Therapies Consumption Value Market Share by Region (2019-2030)
 Figure 18. Global Anti-VEGF Therapies Consumption Value Market Share by Region in 2023
 Figure 19. North America Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 20. Europe Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 21. Asia-Pacific Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 22. South America Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 23. Middle East & Africa Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 24. Company Three Recent Developments and Future Plans
 Figure 25. Global Anti-VEGF Therapies Revenue Share by Players in 2023
 Figure 26. Anti-VEGF Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2023
 Figure 27. Market Share of Anti-VEGF Therapies by Player Revenue in 2023
 Figure 28. Top 3 Anti-VEGF Therapies Players Market Share in 2023
 Figure 29. Top 6 Anti-VEGF Therapies Players Market Share in 2023
 Figure 30. Global Anti-VEGF Therapies Consumption Value Share by Type (2019-2024)
 Figure 31. Global Anti-VEGF Therapies Market Share Forecast by Type (2025-2030)
 Figure 32. Global Anti-VEGF Therapies Consumption Value Share by Application (2019-2024)
 Figure 33. Global Anti-VEGF Therapies Market Share Forecast by Application (2025-2030)
 Figure 34. North America Anti-VEGF Therapies Consumption Value Market Share by Type (2019-2030)
 Figure 35. North America Anti-VEGF Therapies Consumption Value Market Share by Application (2019-2030)
 Figure 36. North America Anti-VEGF Therapies Consumption Value Market Share by Country (2019-2030)
 Figure 37. United States Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 38. Canada Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 39. Mexico Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 40. Europe Anti-VEGF Therapies Consumption Value Market Share by Type (2019-2030)
 Figure 41. Europe Anti-VEGF Therapies Consumption Value Market Share by Application (2019-2030)
 Figure 42. Europe Anti-VEGF Therapies Consumption Value Market Share by Country (2019-2030)
 Figure 43. Germany Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 44. France Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 45. United Kingdom Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 46. Russia Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 47. Italy Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 48. Asia-Pacific Anti-VEGF Therapies Consumption Value Market Share by Type (2019-2030)
 Figure 49. Asia-Pacific Anti-VEGF Therapies Consumption Value Market Share by Application (2019-2030)
 Figure 50. Asia-Pacific Anti-VEGF Therapies Consumption Value Market Share by Region (2019-2030)
 Figure 51. China Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 52. Japan Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 53. South Korea Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 54. India Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 55. Southeast Asia Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 56. Australia Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 57. South America Anti-VEGF Therapies Consumption Value Market Share by Type (2019-2030)
 Figure 58. South America Anti-VEGF Therapies Consumption Value Market Share by Application (2019-2030)
 Figure 59. South America Anti-VEGF Therapies Consumption Value Market Share by Country (2019-2030)
 Figure 60. Brazil Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 61. Argentina Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 62. Middle East & Africa Anti-VEGF Therapies Consumption Value Market Share by Type (2019-2030)
 Figure 63. Middle East & Africa Anti-VEGF Therapies Consumption Value Market Share by Application (2019-2030)
 Figure 64. Middle East & Africa Anti-VEGF Therapies Consumption Value Market Share by Country (2019-2030)
 Figure 65. Turkey Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 66. Saudi Arabia Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 67. UAE Anti-VEGF Therapies Consumption Value (2019-2030) & (USD Million)
 Figure 68. Anti-VEGF Therapies Market Drivers
 Figure 69. Anti-VEGF Therapies Market Restraints
 Figure 70. Anti-VEGF Therapies Market Trends
 Figure 71. Porters Five Forces Analysis
 Figure 72. Anti-VEGF Therapies Industrial Chain
 Figure 73. Methodology
 Figure 74. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Roche
Eli Lilly
Pfizer
Regeneron Pharmaceuticals
Novartis
Alphamab Oncology
Chengdu Kanghong Pharmaceutical

Related Reports

Global Anti-VEGF Therapies Supply, Demand and Key Producers, 2024-2030

Global Anti-VEGF Therapies Supply, Demand and Key Producers, 2024-2030

date 25 Jul 2024

date Medical Care

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

Product Tags

Anti-VEGF Therapies

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>